CN1897952B - 中性白细胞增多抑制剂 - Google Patents

中性白细胞增多抑制剂 Download PDF

Info

Publication number
CN1897952B
CN1897952B CN2004800381582A CN200480038158A CN1897952B CN 1897952 B CN1897952 B CN 1897952B CN 2004800381582 A CN2004800381582 A CN 2004800381582A CN 200480038158 A CN200480038158 A CN 200480038158A CN 1897952 B CN1897952 B CN 1897952B
Authority
CN
China
Prior art keywords
hydrogen atom
formula
purposes
halogen atom
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800381582A
Other languages
English (en)
Chinese (zh)
Other versions
CN1897952A (zh
Inventor
岩間武久
水流添畅智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Corp
Publication of CN1897952A publication Critical patent/CN1897952A/zh
Application granted granted Critical
Publication of CN1897952B publication Critical patent/CN1897952B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN2004800381582A 2003-12-26 2004-12-22 中性白细胞增多抑制剂 Expired - Fee Related CN1897952B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003433747 2003-12-26
JP433747/2003 2003-12-26
PCT/JP2004/019199 WO2005063250A1 (ja) 2003-12-26 2004-12-22 好中球増多抑制剤

Publications (2)

Publication Number Publication Date
CN1897952A CN1897952A (zh) 2007-01-17
CN1897952B true CN1897952B (zh) 2010-12-08

Family

ID=34736527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800381582A Expired - Fee Related CN1897952B (zh) 2003-12-26 2004-12-22 中性白细胞增多抑制剂

Country Status (12)

Country Link
US (2) US20070117806A1 (cg-RX-API-DMAC7.html)
EP (1) EP1698339A4 (cg-RX-API-DMAC7.html)
JP (1) JP4688681B2 (cg-RX-API-DMAC7.html)
KR (2) KR20060125816A (cg-RX-API-DMAC7.html)
CN (1) CN1897952B (cg-RX-API-DMAC7.html)
AU (1) AU2004308806B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417200A (cg-RX-API-DMAC7.html)
CA (1) CA2549672C (cg-RX-API-DMAC7.html)
IL (1) IL176473A (cg-RX-API-DMAC7.html)
RU (1) RU2356555C2 (cg-RX-API-DMAC7.html)
TW (1) TW200522962A (cg-RX-API-DMAC7.html)
WO (1) WO2005063250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101537006B (zh) * 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
CN102133217B (zh) * 2010-01-27 2013-07-24 中国科学院上海药物研究所 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329492A (zh) * 1998-12-07 2002-01-02 日产化学工业株式会社 勃起功能障碍治疗剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208124B (en) * 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
KR100559192B1 (ko) * 1997-08-28 2006-03-13 닛산 가가쿠 고교 가부시키 가이샤 혈관신생 촉진제 및 혈관신생 작용증강제
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
KR100573376B1 (ko) * 1998-09-01 2006-04-25 닛산 가가쿠 고교 가부시키 가이샤 척추관 협착증 치료제
GB9824160D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
DK1163256T3 (da) * 1999-03-23 2004-06-28 Hollis Eden Pharmaceuticals Hemihydrat af 16.alfa.-bromepiandrosteron
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329492A (zh) * 1998-12-07 2002-01-02 日产化学工业株式会社 勃起功能障碍治疗剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
R. E. Howell,等.Inhibition of Antigen-induced Pulmonary Eosinophilia andNeutrophilia by Selective Inhibitors of PhosphodiesteraseTypes 3 or 4 in Brown Norway Rats.Pulmonary Pharmacology8 2-3.1995,8(2),83-89.
R. E. Howell等.Inhibition of Antigen-induced Pulmonary Eosinophilia andNeutrophilia by Selective Inhibitors of PhosphodiesteraseTypes 3 or 4 in Brown Norway Rats.Pulmonary Pharmacology8 2-3.1995,8(2),83-89. *
周新.COPD发病机制研究进展.临床肺科杂志6 3.2001,6(3),47-48.
周新.COPD发病机制研究进展.临床肺科杂志6 3.2001,6(3),47-48. *

Also Published As

Publication number Publication date
JPWO2005063250A1 (ja) 2007-07-19
TWI341729B (cg-RX-API-DMAC7.html) 2011-05-11
KR101293350B1 (ko) 2013-08-05
KR20100019542A (ko) 2010-02-18
WO2005063250A1 (ja) 2005-07-14
US20070117806A1 (en) 2007-05-24
EP1698339A1 (en) 2006-09-06
EP1698339A4 (en) 2009-06-17
AU2004308806B2 (en) 2009-10-29
AU2004308806A1 (en) 2005-07-14
BRPI0417200A (pt) 2007-02-06
CN1897952A (zh) 2007-01-17
IL176473A (en) 2013-06-27
AU2004308806B9 (en) 2010-01-28
KR20060125816A (ko) 2006-12-06
CA2549672A1 (en) 2005-07-14
RU2356555C2 (ru) 2009-05-27
HK1098378A1 (en) 2007-07-20
JP4688681B2 (ja) 2011-05-25
IL176473A0 (en) 2006-10-05
CA2549672C (en) 2010-06-22
TW200522962A (en) 2005-07-16
RU2006127040A (ru) 2008-02-10
US20080306080A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
TWI296525B (en) Novel combination of nonsedating antihistamines with substances which influence leukotriene action, for the treatment of rhinitis/conjunctivitis
US20100204210A1 (en) Method for treating pulmonary diseases using rho kinase inhibitor compounds
AU2002363443B2 (en) New uses for anti-malarial therapeutic agents
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JPH09507216A (ja) ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
TW200843750A (en) New combination 665
JPH09506622A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
CN104220073A (zh) Ccr3-抑制剂的用途
JP2005513031A (ja) 肺線維症の処置のためのｐｐａｒアクチベーターの使用
JP2003523944A (ja) Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
CN110267660A (zh) 含布罗莫结构域蛋白4(brd4)的抑制剂
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
CN1897952B (zh) 中性白细胞增多抑制剂
SK8572003A3 (en) Histamine receptor antagonists
CN100506230C (zh) 血管内膜增厚抑制剂
CN117999073A (zh) 纳多洛尔通过阻断抑制蛋白-2途径来治疗慢性阻塞性肺病的用途
JP2023503723A (ja) 好酸球性喘息の処置のためのｍａｓｉｔｉｎｉｂの使用
CN118634190B (zh) 一种三唑类药物混悬液及其制备方法和用途
JP2004002454A (ja) 消化管運動抑制剤
PT1685849E (pt) Inibidores de pde4 para o tratamento da cistite intersticial
HK1098378B (en) Neutrophilia inhibitor
CN101631538B (zh) 用于治疗慢性阻塞性肺病的药物
JPWO2000012091A1 (ja) 脊柱管狭窄症治療剤
JPWO2004087148A1 (ja) 肺疾患の治療および／または予防剤
KR20180065223A (ko) 천식의 치료 또는 완화용 약학 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098378

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098378

Country of ref document: HK

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: TAISHO PHARMACEUTICAL CO., LTD.

Effective date: 20150422

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150422

Address after: Tokyo, Japan

Patentee after: Nissan Chemical Industries Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Nissan Chemical Industries Co., Ltd.

Patentee before: Taisho Pharmaceutical Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101208

Termination date: 20171222

CF01 Termination of patent right due to non-payment of annual fee